[Pharmacokinetics of transbronchially injected flconazole in pulmonary aspergillosis].
A 68-year-old woman had a pulmonary aspergilloma in the left upper lobe, with old cavitary pulmonary tuberculosis. Surgery was not possible because of marginal ventilation, and the patient was treated by transbronchial injection of Fulconazole. After five injections of 50 mg of Fulconazole, the fungus ball had decreased in size. To study the pharmacokinetics of Fulconazole after transbronchial injection, its concentration in serum was measured. The values of serum Fulconazole concentration were 0.7 microgram/ml at 1 h, 0.8 microgram/ml at 4 h, 0.8 microgram/ml at 8 h, 0.7 microgram/ml at 12 h, 0.7 microgram/ml at 24 h, and 0 microgram/ml at 48 h after transbronchial injection. These results indicate that Fulconazole was absorbed well. Furthermore, these values are equal to those obtained after intravenous administration of 50 mg and are higher than those obtained after intravenous administration of 25 mg. Fulconazole may have been absorbed via the bronchial epithelium, because of destruction of alveoli, connective tissue proliferation in the cavitary wall and secondary bronchiectasis.
Onizuka
O
O
Department of Internal Medicine, National Nishibeppu Hospital, Oita, Japan.
Kawano
M
M
Takikawa
S
S
Sugihara
R
R
Ando
H
H
D000368:Aged; D001228:Aspergillosis / Q000188:drug therapy / Q000378:metabolism*; D001980:Bronchi / Q000378:metabolism; D004848:Epithelium / Q000378:metabolism; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D015552:Injections, Intralesional; D008172:Lung Diseases, Fungal / Q000188:drug therapy / Q000378:metabolism*; D014397:Tuberculosis, Pulmonary / Q000150:complications
D015725:Fluconazole